Mumps in a highly vaccinated Marshallese community in Arkansas, USA: an outbreak report

Viral Infections, Non-HIV

Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control

N Engl J Med.

Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M, Marin M, Riley J, Feikin DR, Patel M, Quinlisk P

doi: 10.1056/NEJMoa1703309.

Viral Infections, Non-HIV

Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016

Vaccine.

Myers TR, McNeil MM, Ng CS, Li R, Marquez PL, Moro PL, Omer SB, Cano MV

doi: 10.1016/j.vaccine.

Viral Infections, Non-HIV

Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016

Vaccine

Myers TR, McNeil MM, Ng CS, Li R, Marquez PL, Moro PL, Omer SB, Cano MV

doi: 10.1016/j.vaccine.2020.07.039

Viral Infections, Non-HIV

Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial

Lancet Infect Dis.

Povey M, Henry O, Riise Bergsaker MA, Chlibek R, Esposito S, Flodmark CE, Gothefors L, Man S, Silfverdal SA, Štefkovičová M, Usonis V, Wysocki J, Gillard P, Prymula R

doi: 10.1016/S1473-3099(18)30716-3.

Viral Infections, Non-HIV

Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review

Vaccine.

Walker EJ, MacDonald NE, Islam N, Le Saux N, Top KA, Fell DB

doi: 10.1016/j.vaccine.2019.02.031.

Viral Infections, Non-HIV

Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials

Vaccine.

Whitworth HS, Gallagher KE, Howard N, Mounier-Jack S, Mbwanji G, Kreimer AR, Basu P, Kelly H, Drolet M, Brisson M, Watson-Jones D

doi: 10.1016/j.vaccine.2019.12.017.

Viral Infections, Non-HIV

Transcriptomic profiling of different responder types in adults after a Priorix® vaccination

Vaccine.

Bartholomeus E, De Neuter N, Suls A, Elias G, van der Heijden S, Keersmaekers N, Jansens H, Van Tendeloo V, Beutels P, Laukens K, Ogunjimi B, Mortier G, Meysman P, Van Damme P

doi: 10.1016/j.vaccine.2020.03.004.

Viral Infections, Non-HIV

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Vaccine

Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, Leav B, mRNA-1273 Study Group.

doi: 10.1016/j.vaccine.2021.02.007

Viral Infections, Non-HIV

Who is at risk of 13-valent conjugated pneumococcal vaccine failure?

Vaccine.

Yildirim M, Keskinocak P, Pelton S, Pickering L, Yildirim I

doi: 10.1016/j.vaccine.2019.12.060.

Related content

Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control

Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016

Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016

Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial

Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review

Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials

Transcriptomic profiling of different responder types in adults after a Priorix® vaccination

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Who is at risk of 13-valent conjugated pneumococcal vaccine failure?